Abstract:Acute myeloid leukemia (AML) is a group of highly aggressive malignancies with a 5-year overall survival (OS) of <40%. Cell overgrowth with apoptosis resistance is a hallmark of AML, but little is known about how it occurs. In this study, we show that dysregulated the largest subunit of RNA polymerase II (RPB1) encoded by POLR2A gene is critically involved in this hallmark in AML. qRT-PCR and RNA-seq results showed that POLR2A mRNA were significantly overexpressed in 76.87% (113/147) compared with normal hematopoietic cells(1.5526 versus 0.8447, P<0.001). Western blotting analysis revealed that RPB1 protein is also aberrantly activated in 68.14%(67/113) of AML patients but rare or even absent in normal hematopoietic cells, (0.7889 versus 0.0509, P<0.01). TCGA data analysis indicated that aberrant activation of POLR2A mRNA occurred predominantly in AML, CHOL and THYM, but not in most other types of cancers. Importantly, we observed that RPB1 expression levels were closely associated with tumor burden and poor prognosis. Notably, we found that POLR2A inhibition induced potent apoptosis and growth inhibition of refractory AML cells. Global transcriptomic analysis reveals that POLR2A knockout selectively depleted an array of AML-related oncogenic and anti-apoptosis genes such as c-MYC, RUNX2, MEIS1, FLT3, CDC25A and BCL-2. Conversely, enforced overexpression of RPB1 exhibits robust enrichment of oncogenes and anti-apoptosis genes, leading to cell overgrowth and drug resistance. Of particular interesting, targeting RPB1 by both genetic and pharmacological molecules could lead complete regression of refractory human AML in mouse models. In conclusion, our findings for the first time reveal that dysregulated RPB1 is a central oncogenic hub that drives overgrowth and drug resistance by coordinately hijacking an array of oncogenic genes and anti-apoptosis factors. Importantly, RPB1 is not absolutely required for the survival of normal hematopoietic cells, which is contrary to the commonly accepted belief that RPB1, the heart of the cellular transcription machinery, is required for all protein-coding genes. These data suggest that targeting RPB1 might be a potential therapeutics for treating refractory/relapse AML.Note: This abstract was not presented at the meeting.Citation Format: Qingfeng Yu, Shu Zheng, Ying Xu, Rongzhen Xu. Dysregulated RPB1 is a key driver of overgrowth and drug resistance in acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 373.

RNA-binding Proteins As Drivers of AML and Novel Therapeutic Targets.

RNA binding protein-directed control of leukemic stem cell evolution and function

Aberrant Activation of RPB1 is Critical for Cell Overgrowth in Acute Myeloid Leukemia.

Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway

3138 – A TWO-STEP IN VIVO CRISPR SCREEN UNVEILS PERVASIVE RNA-BINDING PROTEIN DEPENDENCIES FOR LEUKEMIC STEM CELLS AND IDENTIFIES ELAVL1 AS A THERAPEUTIC TARGET

Functional Role of RBP in Osteosarcoma: Regulatory Mechanism and Clinical Therapy.

RNA Binding of GAPDH Controls Transcript Stability and Protein Translation in Acute Myeloid Leukemia

Abstract 373: Dysregulated RPB1 is a Key Driver of Overgrowth and Drug Resistance in Acute Myeloid Leukemia

RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9

RNA-Binding Proteins in Breast Cancer: Biological Implications and Therapeutic Opportunities

RNA-binding proteins and cancer metastasis.

The Implication of Lncrna Expression Pattern and Potential Function of Lncrna RP4‐576H24.2 in Acute Myeloid Leukemia

Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond.

RNA-binding proteins in tumor progression

Long noncoding RNAs: pivotal regulators in acute myeloid leukemia.

Phase separation-competent FBL promotes early pre-rRNA processing and translation in acute myeloid leukaemia

RNA Binding Proteins as Potential Therapeutic Targets in Colorectal Cancer

Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia

Multiple roles for AU-rich RNA binding proteins in the development of haematologic malignancies and their resistance to chemotherapy

Comprehensive pan-cancer analysis identifies the RNA-binding protein LRPPRC as a novel prognostic and immune biomarker

RNA Demethylase ALKBH5 Selectively Promotes Tumorigenesis and Cancer Stem Cell Self-Renewal in Acute Myeloid Leukemia.